Navigation Links
Argos Therapeutics to Present Corporate Overview and Next Steps in Clinical Development of Arcelis™ Immunotherapy at Lazard Capital Markets 7th Annual Healthcare Conference
Date:11/11/2010

DURHAM, N.C., Nov. 11, 2010 /PRNewswire/ -- Argos Therapeutics today announced that Jeff Abbey, the company's president and chief executive officer, will present a corporate overview and the next steps in the clinical development of Argos' Arcelis™ immunotherapy at the Lazard Capital Markets 7th Annual Healthcare Conference in New York at 11 a.m. EST on Wednesday, Nov. 17, 2010.  The conference will take place at The St. Regis New York.

Argos is in the process of securing funding to begin a Phase 3 trial in renal cell carcinoma (RCC) with its Arcelis immunotherapy, AGS 003, in mid-2011.  The company recently presented favorable progression-free survival and safety results from an ongoing Phase 2 trial for AGS 003 in combination with sunitinib. Argos' Arcelis HIV program, AGS-004, is also currently being tested in a double-blind, placebo controlled, randomized Phase 2b study co-funded by the NIH to further demonstrate that it is a feasible treatment option of HIV-1 infected patients.

About the Arcelis™ Technology

Arcelis is Argos' proprietary technology for personalizing RNA-loaded dendritic cell immunotherapies for cancer, HIV and other infectious diseases. This platform is based on optimizing a patient's own (autologous) dendritic cells to trigger a tumor- or pathogen-specific immune response. To address the challenge of the unique genetic profile of each patient's disease and the genetic mutations of that disease, Argos loads the autologous dendritic cells with a sample of messenger RNA ("mRNA") isolated from the patient's disease. Through this process, dendritic cells can potentially prime immune responses to the entire antigenic repertoire, resulting in an immunotherapeutic that is customized to the patient's specific disease.

About Argos Therapeutics, Inc.Argos is an immunotherapy c
'/>"/>

SOURCE Argos Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
2. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
3. NASDAQ Grants Cell Therapeutics 180-Day Extension to Regain Compliance With Minimum Bid Price Rule
4. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
5. Orexigen® Therapeutics Schedules November 3, 2010 Webcast Discussion of Financial Results for the Third Quarter Ended September 30, 2010
6. United Therapeutics Corporation Reports Third Quarter 2010 Financial Results
7. Cell Therapeutics, Inc. (CTI) to Report Third Quarter 2010 Financial Results on October 28
8. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
9. United Therapeutics Corporation to Announce Third Quarter 2010 Financial Results Before Market Open on Thursday, October 28, 2010
10. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
11. Precision Therapeutics President and CEO Sean McDonald Recognized as Pittsburgh Technology Council Tech 50 CEO of the Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Switzerland (PRWEB) , ... August 27, 2015 , ... ... on customers’ weighing needs and expertly narrows down the product choices to a ... selection criteria pares down the list to models that fit best with the ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... presented new data on the relationship of genetics and hypertension at the ... Heart Disease in Vancouver, British Columbia, Canada. The event, which boasts an extensive ...
(Date:8/26/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended June 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Oral Amp B program, rapidly advancing towards the ... Rae , President & CEO of iCo Therapeutics. "We ...
(Date:8/26/2015)... ... August 26, 2015 , ... ... investment in the development and manufacture of highly valued cardiac markers used in ... team's extensive expertise with protein chemistry has led to the development and commercialization ...
Breaking Biology Technology:METTLER TOLEDO Updates Online Scale Selection Tool 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2
... (Nasdaq: NXTM ), a leading manufacturer of innovative ... Officer,and Robert S. Brown, Chief Financial Officer, will be ... 6, 2008 at Le Parker,Meridien Hotel in New York., ... 6th at,2:30 p.m. ET. To listen to the audio ...
... N.J., Sept. 30 Palatin,Technologies, Inc. (Amex: PTN ) will discuss the fourth quarter ... on corporate developments during a conference call and webcast on,September 30, 2008 at 11:15 a.m. ... September 30, 2008 at Call ... 11:15 a.m. ET ...
... introduced for the first time in the U.S. at the 16th annual ... on Oct. 2-4. , ... HOUSTON (Business Wire EON) September 30, ... assist device (VAD) that benefited from years of hands-on leadership and support ...
Cached Biology Technology:NxStage Medical to Present at JMP Securities Healthcare Focus Conference 2Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008 2 The Modern DeBakey VAD™ To Be Introduced For the First Time in the U.S. : HeartAssist 5™ Pediatric VAD Features Industry Exclusive Direct Blood Flow Measurement System 2 The Modern DeBakey VAD™ To Be Introduced For the First Time in the U.S. : HeartAssist 5™ Pediatric VAD Features Industry Exclusive Direct Blood Flow Measurement System 3
(Date:8/18/2015)... , Aug. 18, 2015  Navitas ... key contributor to the Submission Content Management ... IRISS, a non-profit forum. Dedicated to the Implementation ... a neutral platform for industry, vendors, health ... information and work towards a standard method ...
(Date:8/17/2015)... 17, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market and creator of ... for Q4 2015. The new marketing campaign is being ... Amplitude Marketing Group ( http://amplitudemarketing.com/ ) and TPMG ( ... leader in retail driven marketing and brand awareness and ...
(Date:8/12/2015)... As the digital payment services ... advanced biometrics technology is accelerating beyond expectations.  While the ... using their credit cards, the digital currency, mobile payment ... services led by companies in the space such as ... (NASDAQ: GOOG ), Apple Inc. (NASDAQ: AAPL ...
Breaking Biology News(10 mins):Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6
... that the bacterium that causes dysentery uses a 'sword ... research published today in Science, the team from Imperial ... the bacteria which causes dysentery, is able to invade ... , They found that shigella was able to infect ...
... 99 percent of the genes in the adult body. That's ... of bacteria that normally live on and in us. , ... to researchers at the School of Medicine will help fill ... for isolating, sequencing and analyzing the genomes of "friendly" bacteria ...
... in the journal Blood, Yale scientists identify the molecular triggers ... expand into large populations of malignant lymphocytes. , CTCL is ... blood cells of the immune system. Finding CTCL triggering factors ... Director of the Yale Cancer Center, and professor and chair ...
Cached Biology News:W.M. Keck Foundation funds study of friendly microbes 2W.M. Keck Foundation funds study of friendly microbes 3Source of molecular triggers in cutaneous T cell lymphoma identified 2
...
... to high-speed analytical techniques, the AutoTrace SPE is a powerful, high-throughput workstation dedicated ... sample loading and elution steps for large volumes aqueous solution extractions (up to ... ... ...
Cell Culture Flask, nontreated polystyrene...
Automated Cell Culture Flask...
Biology Products: